Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)

NCT04221893 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04221893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04221893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Lead sponsor
University of California, San Francisco
Phase
Not applicable
Overall status
Recruiting
Start date
August 7, 2020
Completion date
April 30, 2028
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic anal canal carcinoma, metastatic colorectal carcinoma, metastatic esophageal carcinoma, metastatic gastric carcinoma, metastatic gastroesophageal junction adenocarcinoma, metastatic hepatocellular carcinoma, metastatic malignant digestive system neoplasm, metastatic small intestinal carcinoma, pancreatobiliary carcinoma, pathologic stage iv gastric cancer ajcc v8, pathologic stage iva esophageal adenocarcinoma ajcc v8, pathologic stage iva esophageal squamous cell carcinoma ajcc v8, pathologic stage ivb esophageal adenocarcinoma ajcc v8, pathologic stage ivb esophageal squamous cell carcinoma ajcc v8, pathologic stage ivb gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iv gastric cancer ajcc v8, postneoadjuvant therapy stage iv gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iva gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage ivb gastroesophageal junction adenocarcinoma ajcc v8, stage iv adenocarcinoma of the gastroesophageal junction, stage iv anal cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv esophageal adenocarcinoma, stage iv esophageal squamous cell carcinoma, stage iv gastric cancer, stage iv hepatocellular carcinoma ajcc v8, stage iva adenocarcinoma of the gastroesophageal junction, stage iva colorectal cancer ajcc v8, stage iva esophageal adenocarcinoma, stage iva esophageal squamous cell carcinoma, stage iva gastric cancer, stage iva hepatocellular carcinoma ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivb esophageal adenocarcinoma, stage ivb esophageal squamous cell carcinoma, stage ivb gastric cancer, stage ivb gastroesophageal junction adenocarcinoma, stage ivb hepatocellular carcinoma ajcc v8, stage ivc colorectal cancer ajcc v8